Cargando…

IGF1 receptor-targeted black TiO(2) nanoprobes for MRI-guided synergetic photothermal-chemotherapy in drug resistant pancreatic tumor

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignant tumors with features of matrix barrier caused poor drug permeability, and susceptibility to drug resistance. Herein, a PDAC and its stromal cell dual-targeted photothermal-chemotherapy strategy is explored to loosen the matrix...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Kaiwei, Jin, Lufei, Xu, Liu, Zhu, Yuchao, Hong, Lu, Pan, Chunshu, Li, Yanying, Yao, Junlie, Zou, Ruifen, Tang, Weiwei, Wang, Jianhua, Wu, Aiguo, Ren, Wenzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258211/
https://www.ncbi.nlm.nih.gov/pubmed/35794573
http://dx.doi.org/10.1186/s12951-022-01525-3
_version_ 1784741496104157184
author Xu, Kaiwei
Jin, Lufei
Xu, Liu
Zhu, Yuchao
Hong, Lu
Pan, Chunshu
Li, Yanying
Yao, Junlie
Zou, Ruifen
Tang, Weiwei
Wang, Jianhua
Wu, Aiguo
Ren, Wenzhi
author_facet Xu, Kaiwei
Jin, Lufei
Xu, Liu
Zhu, Yuchao
Hong, Lu
Pan, Chunshu
Li, Yanying
Yao, Junlie
Zou, Ruifen
Tang, Weiwei
Wang, Jianhua
Wu, Aiguo
Ren, Wenzhi
author_sort Xu, Kaiwei
collection PubMed
description Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignant tumors with features of matrix barrier caused poor drug permeability, and susceptibility to drug resistance. Herein, a PDAC and its stromal cell dual-targeted photothermal-chemotherapy strategy is explored to loosen the matrix and reverse drug resistance. To achieve this goal, black TiO(2)-Gd nanocomposites were conjugated with insulin like growth factor 1 (IGF1), and loaded with gemcitabine (GEM) to construct bTiO(2)-Gd-IGF1-GEM nanoprobes. In vitro results show that under 808 nm near-infrared irradiation, killing effect of the nanoprobes on drug-resistant MIA PaCa-2 cell is 3.3 times than that of GEM alone. In vivo experiments indicate the synergetic photothermal-chemotherapy not only loosens fibrous matrix of pancreatic tumor model, but also dramatically inhibits tumor growth, and almost completely eradicates the tumor after 12 days of treatment. In addition, relaxation rate of the nanoprobes is 8.2 times than commercial contrast agent Magnevist, therefore boosts the signal of magnetic resonance imaging in pancreatic tumor. In conclusion, our results reinforce that the prepared nanoprobes are promising to break matrix barrier and overcome drug resistance in PDAC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01525-3.
format Online
Article
Text
id pubmed-9258211
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92582112022-07-07 IGF1 receptor-targeted black TiO(2) nanoprobes for MRI-guided synergetic photothermal-chemotherapy in drug resistant pancreatic tumor Xu, Kaiwei Jin, Lufei Xu, Liu Zhu, Yuchao Hong, Lu Pan, Chunshu Li, Yanying Yao, Junlie Zou, Ruifen Tang, Weiwei Wang, Jianhua Wu, Aiguo Ren, Wenzhi J Nanobiotechnology Research Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignant tumors with features of matrix barrier caused poor drug permeability, and susceptibility to drug resistance. Herein, a PDAC and its stromal cell dual-targeted photothermal-chemotherapy strategy is explored to loosen the matrix and reverse drug resistance. To achieve this goal, black TiO(2)-Gd nanocomposites were conjugated with insulin like growth factor 1 (IGF1), and loaded with gemcitabine (GEM) to construct bTiO(2)-Gd-IGF1-GEM nanoprobes. In vitro results show that under 808 nm near-infrared irradiation, killing effect of the nanoprobes on drug-resistant MIA PaCa-2 cell is 3.3 times than that of GEM alone. In vivo experiments indicate the synergetic photothermal-chemotherapy not only loosens fibrous matrix of pancreatic tumor model, but also dramatically inhibits tumor growth, and almost completely eradicates the tumor after 12 days of treatment. In addition, relaxation rate of the nanoprobes is 8.2 times than commercial contrast agent Magnevist, therefore boosts the signal of magnetic resonance imaging in pancreatic tumor. In conclusion, our results reinforce that the prepared nanoprobes are promising to break matrix barrier and overcome drug resistance in PDAC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01525-3. BioMed Central 2022-07-06 /pmc/articles/PMC9258211/ /pubmed/35794573 http://dx.doi.org/10.1186/s12951-022-01525-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Xu, Kaiwei
Jin, Lufei
Xu, Liu
Zhu, Yuchao
Hong, Lu
Pan, Chunshu
Li, Yanying
Yao, Junlie
Zou, Ruifen
Tang, Weiwei
Wang, Jianhua
Wu, Aiguo
Ren, Wenzhi
IGF1 receptor-targeted black TiO(2) nanoprobes for MRI-guided synergetic photothermal-chemotherapy in drug resistant pancreatic tumor
title IGF1 receptor-targeted black TiO(2) nanoprobes for MRI-guided synergetic photothermal-chemotherapy in drug resistant pancreatic tumor
title_full IGF1 receptor-targeted black TiO(2) nanoprobes for MRI-guided synergetic photothermal-chemotherapy in drug resistant pancreatic tumor
title_fullStr IGF1 receptor-targeted black TiO(2) nanoprobes for MRI-guided synergetic photothermal-chemotherapy in drug resistant pancreatic tumor
title_full_unstemmed IGF1 receptor-targeted black TiO(2) nanoprobes for MRI-guided synergetic photothermal-chemotherapy in drug resistant pancreatic tumor
title_short IGF1 receptor-targeted black TiO(2) nanoprobes for MRI-guided synergetic photothermal-chemotherapy in drug resistant pancreatic tumor
title_sort igf1 receptor-targeted black tio(2) nanoprobes for mri-guided synergetic photothermal-chemotherapy in drug resistant pancreatic tumor
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258211/
https://www.ncbi.nlm.nih.gov/pubmed/35794573
http://dx.doi.org/10.1186/s12951-022-01525-3
work_keys_str_mv AT xukaiwei igf1receptortargetedblacktio2nanoprobesformriguidedsynergeticphotothermalchemotherapyindrugresistantpancreatictumor
AT jinlufei igf1receptortargetedblacktio2nanoprobesformriguidedsynergeticphotothermalchemotherapyindrugresistantpancreatictumor
AT xuliu igf1receptortargetedblacktio2nanoprobesformriguidedsynergeticphotothermalchemotherapyindrugresistantpancreatictumor
AT zhuyuchao igf1receptortargetedblacktio2nanoprobesformriguidedsynergeticphotothermalchemotherapyindrugresistantpancreatictumor
AT honglu igf1receptortargetedblacktio2nanoprobesformriguidedsynergeticphotothermalchemotherapyindrugresistantpancreatictumor
AT panchunshu igf1receptortargetedblacktio2nanoprobesformriguidedsynergeticphotothermalchemotherapyindrugresistantpancreatictumor
AT liyanying igf1receptortargetedblacktio2nanoprobesformriguidedsynergeticphotothermalchemotherapyindrugresistantpancreatictumor
AT yaojunlie igf1receptortargetedblacktio2nanoprobesformriguidedsynergeticphotothermalchemotherapyindrugresistantpancreatictumor
AT zouruifen igf1receptortargetedblacktio2nanoprobesformriguidedsynergeticphotothermalchemotherapyindrugresistantpancreatictumor
AT tangweiwei igf1receptortargetedblacktio2nanoprobesformriguidedsynergeticphotothermalchemotherapyindrugresistantpancreatictumor
AT wangjianhua igf1receptortargetedblacktio2nanoprobesformriguidedsynergeticphotothermalchemotherapyindrugresistantpancreatictumor
AT wuaiguo igf1receptortargetedblacktio2nanoprobesformriguidedsynergeticphotothermalchemotherapyindrugresistantpancreatictumor
AT renwenzhi igf1receptortargetedblacktio2nanoprobesformriguidedsynergeticphotothermalchemotherapyindrugresistantpancreatictumor